Applications of 2-Amino-4-(4-Chloro-Phenyl)-Thiophene-3-Carboxylic Acid Ethyl Ester in Industrial Manufacturing

2-Amino-4-(4-chloro-phenyl)-thiophene-3-carboxylic acid ethyl ester supports multiple downstream manufacturing operations with stringent technical, compliance, and production requirements. Below we detail core industrial segments utilizing this compound as an advanced intermediate, with direct relevance to pharmaceutical synthesis, agrochemical R&D, and specialty chemical manufacturing.

1. Pharmaceutical Active Pharmaceutical Ingredient (API) Intermediate

This molecule serves as a targeted heterocyclic intermediate in the multi-step synthesis of selected small-molecule APIs, especially for cardiovascular, anti-inflammatory, and central nervous system therapeutic categories. Manufacturers introduce this raw material at the core coupling stage, where its unique substitution pattern promotes select functionalization and rapid scale-up. Process chemists differentiate the precise charge and substitution profile based on target molecule requirements, solvent compatibility, and route optimization under cGMP scrutiny.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for APIs
• US FDA 21 CFR Part 211 – Finished Pharmaceuticals
• European Pharmacopoeia monograph compliance where applicable
• Quality control under ISO 9001:2015

Typical usage ratio

• 0.8 to 1.1 molar equivalents based on target final API batch size
• Adjustment according to required coupling routes and yield optimization
• Purity typically >99.0% for process stages involving salt formation
• Solvent volumes set by reactors and GMP process safety limits

Downstream process integration

• Charged at the acylation or amination reaction step in API production
• Handled in clean-room environments as part of automated synthesis lines
• Subject to in-process HPLC and NMR validation pre-coupling
• Integrated with crystallization or extraction modules for post-reaction workup

Final product types

• Sartans, thienopyridine antiplatelet drug intermediates
• Small molecule CNS agent intermediates
• Custom contract pharmaceutical intermediates
• Customer-specific fine chemical building blocks for finished drugs

2. Agrochemical Synthesis Intermediate

This ester acts as a core scaffold in the development and pilot-scale production of advanced herbicidal and fungicidal actives. The thiophene-carboxylate backbone introduces stability and bioactivity into proprietary crop protection compounds. Technicians optimize input quantities based on reaction screens and the targeted SAR structure outcomes for agrochemical application. Batch-wise QC involves liquid chromatography and impurity assessment, while waste management processes respond to local EHS standards.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP) for agrochemical R&D
• ISO 9001:2015 quality system for intermediate manufacturing
• Local chemical safety handling requirements e.g., REACH (EU) or TSCA (US)
• Environmental permit requirements for effluent and solid waste streams

Typical usage ratio

• 500 – 800 grams per kilogram of target actives, dependent on SAR optimization
• Process engineers adjust excess or limiting reagent status according to pilot yields
• Technical grade material (98%+) accepted for early process research
• Final specification tailored to end customer’s downstream transformation schedule

Downstream process integration

• Introduced at the precursor cyclization or aryloxyacetate derivatization step
• Integrated directly into continuous-flow synthesis modules in pilot and scale-up
• Subject to staged purification and fractional distillation approaches
• Residue and purity accounted in batch QCPPR (Quality Critical Process Parameter Reports)

Final product types

• Selective pre-emergent herbicide intermediates
• Novel broad-spectrum fungicidal actives
• Plant growth regulator precursors for field application testing
• Seed treatment formulation bases

3. Custom Thienopyridine Synthesis

Research platforms and fine chemical synthesis contractors rely on this compound as a central intermediate for high-purity thienopyridine structures, widely explored for antithrombotic development. Pure batches are charged during specific condensation sequences with careful temperature, solvent, and reactant controls. Production teams frequently adjust reagent ratios in response to analytical feedback and multi-step impurity profiles for regulated clinical trial material supply chains.

Industry compliance standards

• Good Manufacturing Practice (GMP) for Investigational Medicinal Products (EU Guidelines)
• ISO 17025 accredited analytical laboratory protocols
• Controlled substance handling permits (where relevant)
• Traceability under enterprise resource planning (ERP) links

Typical usage ratio

• Precisely 1.0 molar equivalent for condensation step with thienopyridine core
• Yield monitoring by HPLC triggers additional charge adjustments up to 10%
• High-purity lots only, with documented trace impurity limits (<0.1%)
• Batch documentation and reconciliation required for QP release

Downstream process integration

• Meticulous charging in glovebox or inert-atmosphere synthesis
• Coupled immediately after major salt cleavage or derivatization events
• Downstream transfer into pilot scale or kilo-lab reactors for campaign manufacturing
• Purification by medium-pressure chromatography prior to final salt formation

Final product types

• Antithrombotic agent intermediates (e.g., clopidogrel precursors)
• Proprietary contract research thienopyridines
• Export-grade intermediates for global clinical trial supply
• Diversified custom catalog building blocks

4. Specialty Electronic Chemical Precursor

This ester finds application in the synthesis of advanced organic electronic materials, particularly within the field of organic semiconductors, where the controlled introduction of electron-donating and electron-withdrawing groups influences charge transport and material stability. Materials engineers integrate the compound during the key heterocycle construction process, influencing final device performance. Device makers demand batch-level analytical traceability and process repeatability to ensure end-use conformance in film or device fabrication workflows.

Industry compliance standards

• RoHS Directive 2011/65/EU for electronic components
• ISO 9001:2015 for process quality management
• Customer-specific purity and trace element testing protocols
• Full material disclosure for restricted substances in electronics

Typical usage ratio

• 50 – 200 mg per gram final organic semiconductor batch, depending on layer thickness and substrate type
• Higher concentrations trialed for prototype devices
• Consistency confirmed by batch HPLC and GC measurements
• Lot selection driven by end-user optoelectronic property criteria

Downstream process integration

• Charged during the polymer backbone or oligomerization reaction step
• Handled in inert atmosphere to limit oxidation or hydrolysis
• Final blend integration before spin-coating or film deposition
• Material qualification via electrical and spectroscopic analysis in QC

Final product types

• Organic thin-film transistors (OTFTs)
• OLED device intermediate materials
• Organic photovoltaic cell precursors
• Electronic-grade functionalized polymers